Skip to main navigation Skip to search Skip to main content

Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody

  • Kai Xu
  • , Barry Rockx
  • , Yihu Xie
  • , Blair L. DeBuysscher
  • , Deborah L. Fusco
  • , Zhongyu Zhu
  • , Yee Peng Chan
  • , Yan Xu
  • , Truong Luu
  • , Regina Z. Cer
  • , Heinz Feldmann
  • , Vishwesh Mokashi
  • , Dimiter S. Dimitrov
  • , Kimberly A. Bishop-Lilly
  • , Christopher C. Broder
  • , Dimitar B. Nikolov
  • Memorial Sloan-Kettering Cancer Center
  • University of Texas Medical Branch at Galveston
  • Uniformed Services University of the Health Sciences
  • National Institutes of Health
  • Naval Medical Research Center
  • Henry M. Jackson Foundation
  • University of Manitoba

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Abstract

The henipaviruses, represented by Hendra (HeV) and Nipah (NiV) viruses are highly pathogenic zoonotic paramyxoviruses with uniquely broad host tropisms responsible for repeated outbreaks in Australia, Southeast Asia, India and Bangladesh. The high morbidity and mortality rates associated with infection and lack of licensed antiviral therapies make the henipaviruses a potential biological threat to humans and livestock. Henipavirus entry is initiated by the attachment of the G envelope glycoprotein to host cell membrane receptors. Previously, henipavirus-neutralizing human monoclonal antibodies (hmAb) have been isolated using the HeV-G glycoprotein and a human naïve antibody library. One cross-reactive and receptor-blocking hmAb (m102.4) was recently demonstrated to be an effective post-exposure therapy in two animal models of NiV and HeV infection, has been used in several people on a compassionate use basis, and is currently in development for use in humans. Here, we report the crystal structure of the complex of HeV-G with m102.3, an m102.4 derivative, and describe NiV and HeV escape mutants. This structure provides detailed insight into the mechanism of HeV and NiV neutralization by m102.4, and serves as a blueprint for further optimization of m102.4 as a therapeutic agent and for the development of entry inhibitors and vaccines.

Original languageEnglish
Article numbere1003684
JournalPLoS Pathogens
Volume9
Issue number10
DOIs
StatePublished - Oct 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody'. Together they form a unique fingerprint.

Cite this